Buscar resultados de ensayos clínicos
Prostatic Neoplasms, Castration-Resistant - 21 Studies Found
Estado | Estudiar |
Active, not recruiting |
Nombre del estudio: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2015-10-29 Intervenciones:
|
Suspended |
Nombre del estudio: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2015-12-07 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2014-06-11 Intervenciones: Drug: JNJ-56021927 Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single or |
Recruiting |
Nombre del estudio: IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2017-01-09 Intervenciones:
|
Withdrawn |
Nombre del estudio: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2016-09-15 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2016-07-19 Intervenciones: Drug: Xofigo (Radium-223 dichloride, BAY88-8223 Xofigo is indicated for the treatment of patients with c |
Recruiting |
Nombre del estudio: Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2016-06-14 Intervenciones: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Xofigo treatment will be performed according to the pr |
Recruiting |
Nombre del estudio: Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2015-05-19 Intervenciones: Drug: Radium-223-dichloride (Xofigo, BAY88-8223) according to Summary of Product Characteristics |
Recruiting |
Nombre del estudio: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Condición: Prostatic Neoplasms, Castration-Resistant Fecha: 2014-07-29 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer Condición:
Fecha: 2016-11-14 Intervenciones: |